sciencenewsnet.in

Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel

February 5, 2021 sarah Jonas Blood Cancer, CAR-T cell therapy, Cell Therapy, chimeric antigen receptor T cell (CAR-T) therapy, Immunotherapy

SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.

Research Results

Study: Treatment-related complication for blood cancer patients could be reduced

January 11, 2021 sarah Jonas Blood Cancer, Graft Vs Host

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.

Research Results

Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma

December 7, 2020 sarah Jonas American Society Of Hematology, American Society of Hematology Annual Meeting, ASH 2020, Blood Cancer, Cancer, Dana-Farber Cancer Institute, Diffuse large B-cell lymphoma, Hematology, Lymphoma

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

Research Results

Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

December 5, 2020 sarah Jonas Acute Myeloid Leukemia, American Society Of Hematology, American Society of Hematology Annual Meeting, ASH 2020, Blood Cancer, Dana-Farber Cancer Institute, Hematology, Myelodysplastic Syndrome

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

Research Results

Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants

December 5, 2020 sarah Jonas American Society Of Hematology, American Society of Hematology Annual Meeting, Blood Cancer, Cancer, Dana-Farber Cancer Institute, Hematology, Stem Cell Transplant

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.

Announcement

Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting

December 4, 2020 sarah Jonas ASH annual meeting, Blood Cancer, Cancer Research

Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.

Research Results

Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome

December 4, 2020 sarah Jonas American Society Of Hematology, Blood Cancer, Dana-Farber Cancer Institute, Myelodysplastic Syndrome, Stem Cell Transplant

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Research Results

Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting

December 1, 2020 sarah Jonas American Society Of Hematology, American Society of Hematology Annual Meeting, Blood Cancer, Cancer, CAR T cell therapy, Dana-Farber, Dana-Farber Cancer Institute, hemagtology, Leukemia, Lymphoma, Multiple Myeloma, Stem Cell Transplant

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

Policy

New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma

September 28, 2020 sarah Jonas Blood Cancer, Childhood Cancer, Clinical Practice Guidelines, Hematologic Cancers, hematologic malignancies, Hematology, National Comprehensive Cancer Network, NCCN, nccn guidelines, Pediatric Cancer, pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.

Announcement

New NCCN Resource for Understanding Childhood Leukemia

September 23, 2020 sarah Jonas Acute Lymphoblastic Leukemia, Blood Cancer, Childhood Cancer, Childhood Cancer Awareness Month, Hematologic Cancers, hematologic malignancies, Leukemia, National Comprehensive Cancer Network, NCCN, NCCN Foundation, nccn guidelines, NCCN Guidelines for Patients, Pediatric Acute Lymphoblastic Leukemia, pediatric acute lymphoblastic leukemia (ALL), Pediatric ALL, pediatric leukemia

NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.

Research Results

Roswell Park Study: Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients

August 25, 2020 sarah Jonas Blood Cancer, BMT, Bone Marrow Transplant, Cancer, Cellular Therapy, Organ Transplant, Stem Cell Transplant

Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.

Research Results

2 immunotherapies merged into single, more effective treatment

July 23, 2020 sarah Jonas Blood Cancer, Cancer, CAR T cell therapy, Immunotherapy, Leukemia, Natural Killer Cells

Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.

← Previous